NCT07025759 Effects of Peripheral Magnetic Stimulation on Cortical Excitability in Healthy Individuals
| NCT ID | NCT07025759 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Universidade Federal de Pernambuco |
| Condition | Healthy Individuals |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2022-10-01 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 18 participants in total. It began in 2022-10-01 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates the immediate effects of different parameters (frequency, intensity, and pulse number) of peripheral magnetic stimulation (rPMS) on cortical excitability in healthy individuals. Using a randomized, double-blind crossover design, the research aims to identify optimal stimulation protocols for modulating neural activity. Outcomes include measurements of motor-evoked potentials (MEPs), intracortical inhibition (ICI), and facilitation (ICF). Findings may enhance non-invasive therapeutic strategies for neurological disorders.
Eligibility Criteria
Inclusion criteria: Healthy adults aged 18-40 years, both sexes, right-handed (confirmed via Edinburgh Handedness Inventory), and for females, consistent use of contraceptive medication to mitigate hormonal influences on nervous system excitability. Exclusion criteria: Pregnancy; history of seizures or epilepsy; metallic implants in the head, spine, face, or heart; diagnosed neurological or musculoskeletal conditions interfering with assessments or interventions; or use of substances altering nervous system excitability.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07025759 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Healthy Individuals. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07025759 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07025759 currently recruiting?
Yes, NCT07025759 is actively recruiting participants. Contact the research team at lana.ufpe@gmail.com for enrollment information.
Where is the NCT07025759 trial being conducted?
This trial is being conducted at Recife, Brazil.
Who is sponsoring the NCT07025759 clinical trial?
NCT07025759 is sponsored by Universidade Federal de Pernambuco. The trial plans to enroll 18 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.